Source comparison
Comparison Table: Photoprotection Development Across Dosing Protocols
Clinical implant (afamelanotide) 16mg sustained-release One implant per 60 days 10–14 days 110–130% above baseline 30–40 days post-implant Gold standard for EPP. Delivers consistent plasma levels and predictable photoprotection timeline; not accessible outside
This comparison does not assign a generated winner or score.
- Clinical implant (afamelanotide)
- 16mg sustained-release
- One implant per 60 days
- 10–14 days
- 110–130% above baseline
- 30–40 days post-implant
- Gold standard for EPP. Delivers consistent plasma levels and predictable photoprotection timeline; not accessible outside clinical trials or specific medical conditions
- Injectable loading phase
- 0.5–1.0mg per dose
- 2–3× weekly for 4–6 weeks
- 7–12 days
- 90–120% above baseline
- 28–35 days from start
- Most common research protocol. Requires consistent adherence and proper reconstitution; produces comparable MED increase to implants when dosed correctly
- Low-dose maintenance
- 0.25–0.5mg per dose
- 1–2× weekly ongoing
- Minimal new pigmentation
- Maintains 60–80% of peak protection
- Sustains existing melanin density
- Used after loading phase to preserve photoprotection without continuous escalation; allows gradual fade over 8–12 weeks if discontinued
- High-dose front-loading (off-protocol)
- 1.5–2.0mg per dose
- Daily for 7–14 days
- 5–7 days
- Variable. Often <80% due to uneven distribution
- Unpredictable. Risk of patchy pigmentation
- Not supported by clinical evidence; higher nausea incidence, receptor desensitisation risk, and inconsistent melanin deposition patterns. Avoid this approach